| Name | Title | Contact Details |
|---|
Juvly Aesthetics is the fastest growing aesthetics practice in the United States, expanding since 2014, from a single location in Columbus, Ohio to eleven locations across the United States! Our team has gone from servicing just 10 clients to over 53,000 in five short years! The core of this growth stems from our unique values, which include; providing fantastic, natural-beauty enhancing results, transparent prices, and excellent customer service. Whether you are a client looking for first class services, or an eager employment-seeker, Juvly is the place for you!
UConn Health is a vibrant, integrated academic medical center that is entering an era of unprecedented growth in all three areas of its mission: academics, research, and clinical care. UConn Health is at the center of Bioscience Connecticut, a bold plan introduced by Connecticut Governor Dannel P. Malloy and approved by the Connecticut General Assembly in 2011. The plan will strengthen Connecticut`s position as a national and global leader for bioscience innovation and improve access to quality health care for Connecticut citizens for generations to come. Based in Farmington, Connecticut – a popular suburb of the state`s capitol of Hartford – UConn Health is home to the School of Medicine, School of Dental Medicine, John Dempsey Hospital, UConn Medical Group, UConn Health Partners, University Dentists and a thriving research enterprise. With approximately 5,000 employees, UConn Health is a major economic driver in the region, generating nearly $1 billion annually in gross state product. It is closely linked with the University of Connecticut`s main campus in Storrs through multiple, cross-campus academic projects.
Synectic is a Milford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.
Emergo Group is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.